hospital-based studies and reported mortality is around 2-25% depending on patient's age and strain. [2] Dear Editor, Clostridium difficile is ubiquitous and is prevalent among 5-15% of healthy adults. [1] It was first identified as the cause of antibiotic-associated diarrhoea in 1978. C. difficile associated diarrhoea (CDAD) is under-recognised in India and Asia. Prevalence of CDAD is 2-30% in different
Evaluation of a new molecular method illumigene for detection of Clostridium difficile associated diarrhoea
This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.
The laboratory diagnosis of C. difficile remains a challenge to microbiology laboratories. A significant number of clinical laboratories are currently utilising immunoassays for toxin A/B testing due to its ease of use. However, there are many published reports indicating that utilizing this test alone is not appropriate for toxigenic C. difficile detection. [3] We did a comparative study of two methods for detecting CDAD, one detecting the presence of toxin A and B (VIDAS, bioMerieux, France) and the other DNA amplification assay (Illumigene, Meridian Biosciences, Europe). Seventy-three consecutive stool samples were evaluated from patients with clinically suspected CDAD. Patients on antibiotics with unexplained diarrhoea (3 or more watery, loose or unformed stools per day) at least 48 h after admission were included in this study. Asymptomatic patients and patients on antibiotic treatment for C. difficile were excluded from the study. Samples were processed as soon as it was received in the laboratory as toxins usually degenerate if stored inappropriately leading to false negatives.
The overall disease occurrence was found to be 5.5% in our diarrhoea patient population during the period of study. All our patients were males and the most common age group were patients above 50 years of age. Of the 73 samples tested illumigene could detect 6 cases of CDAD whereas VIDAS could detect only 4. The total assay time was comparable in both assays, but there was a significant difference in the cost per test between the assays. Cost per test by illumigene was almost 4 times higher as compared to VIDAS.
VIDAS C. difficile toxins A and B assay is an automated test which detects the toxins A and B in stool
specimens using the enzyme-linked fluorescent assay technique. The illumigene C. difficile assay detects the pathologic location of pathogenic C. difficile strains which code for both toxin A (tcd A) and toxin B (tcd B) genes.
The current diagnostic options for CDAD are enzyme immunoassay (EIA) for toxins, glutamate dehydrogenase assay, direct cell culture cytotoxin neutralisation and the new gold standard toxigenic culture (culture + cytotoxin assay). [3, 4] The molecular methods are easy to perform, cost effective and capable of detecting all toxigenic strains and are being recognised as standalone tests for the diagnosis of CDAD by the American association of clinical microbiologists. [5] Early diagnosis is very important both in terms of patient management as well as prevention of spread of infection. Although there was not much statistical superiority of illumigene over VIDAS due to the small sample size, two cases of CDAD were picked up by the molecular method, which were missed out by the EIA method. This could have lead to a facility outbreak leading to an increase in health care costs associated with isolation, antibiotics and outbreak management. Therefore, the algorithm for diagnosis of CDAD should take into account not only the cost per test but also other factors such as sensitivity and specificity, positive and negative predictive value and the local prevalence of the disease.
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